Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL) Insider Trading
Directors, officers and holders of more than 10% of LYEL report their trades in its stock on SEC Form 4, within two business days. Each row below is one Form 4 transaction line. The one-letter code says what kind of transaction it was: only P (purchase) and S (sale) are open-market or private trades; awards, option exercises, tax withholding and gifts carry other codes.
Recent Form 4 transactions
The 50 most recent of 103 transactions on file: 2 with code P, 26 with code S and 22 with other codes.
| Date | Insider | Title | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 12, 2026 | Aguirre Jarrad Mattieu | Chief Medical Officer | S Sale | 422 | $8.63 | $3,642 |
| Sep 10, 2026 | Shook David | Chief Medical Officer | S Sale | 500 | $12.70 | $6,350 |
| Sep 10, 2026 | Aguirre Jarrad Mattieu | Chief Medical Officer | A Award | 47,500 | Not measured | Not measured |
| Aug 21, 2026 | Hill Stephen J. | Chief Operating Officer | S Sale | 989 | $15.54 | $15,369 |
| Aug 21, 2026 | Seely Lynn | President and CEO | S Sale | 9,589 | $15.54 | $149,013 |
| Aug 21, 2026 | Lee Gary K. | Chief Scientific Officer | S Sale | 1,457 | $15.54 | $22,642 |
| Aug 10, 2026 | Seely Lynn | President and CEO | S Sale | 390 | $14.34 | $5,593 |
| Aug 10, 2026 | Lee Gary K. | Chief Scientific Officer | S Sale | 131 | $14.34 | $1,879 |
| Aug 10, 2026 | Hill Stephen J. | Chief Operating Officer | S Sale | 89 | $14.34 | $1,276 |
| Aug 10, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | S Sale | 621 | $14.34 | $8,905 |
| Jul 27, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | J Other | 38,500 | Not measured | Not measured |
| Jul 27, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | J Other | 44,000 | Not measured | Not measured |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | S Sale | 10 | $13.70 | $137 |
| Jul 16, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | S Sale | 10 | $13.73 | $137 |
| Jun 29, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | J Other | 76,000 | Not measured | Not measured |
| Jun 15, 2026 | Innovative Cellular Therapeutics Holdings Ltd | 10% Owner | J Other | 66,500 | Not measured | Not measured |
| Jun 10, 2026 | NABEL ELIZABETH G | Director | A Award | 9,250 | Not measured | Not measured |
| Jun 10, 2026 | Shook David | Chief Medical Officer | S Sale | 1,977 | $12.64 | $24,989 |
| Jun 10, 2026 | Bachleda Mark | Director | A Award | 9,250 | Not measured | Not measured |
| Jun 10, 2026 | Klausner Richard | Director | A Award | 9,250 | Not measured | Not measured |
| Jun 10, 2026 | Ramachandra Sumant | Director | A Award | 9,250 | Not measured | Not measured |
| Jun 10, 2026 | RIEFLIN WILLIAM JL | Director | A Award | 9,250 | Not measured | Not measured |
| Jun 10, 2026 | FRIEDMAN CATHY | Director | A Award | 9,250 | Not measured | Not measured |
| Jun 10, 2026 | BRAWLEY OTIS W | Director | A Award | 9,250 | Not measured | Not measured |
| May 11, 2026 | Lee Gary K. | Chief Scientific Officer | S Sale | 130 | $18.92 | $2,460 |
| May 11, 2026 | Seely Lynn | President and CEO | S Sale | 388 | $18.91 | $7,337 |
| May 11, 2026 | Hill Stephen J. | Chief Operating Officer | S Sale | 89 | $18.92 | $1,684 |
| May 11, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | S Sale | 217 | $18.91 | $4,103 |
| Mar 9, 2026 | Shah Smital | Chief Fin. and Bus. Officer | A Award | 140,000 | Not measured | Not measured |
| Mar 6, 2026 | ARCH Venture Fund XIII, L.P. | 10% Owner | P Purchase | 488,090 | $25.61 | $12,499,985 |
| Mar 6, 2026 | ARCH Venture Partners IX, LLC | 10% Owner | P Purchase | 488,090 | $25.61 | $12,499,985 |
| Feb 11, 2026 | Seely Lynn | President and CEO | S Sale | 7,455 | $23.39 | $174,372 |
| Feb 11, 2026 | Lee Gary K. | Chief Scientific Officer | S Sale | 1,671 | $23.39 | $39,085 |
| Feb 11, 2026 | Hill Stephen J. | Chief Operating Officer | S Sale | 1,236 | $23.39 | $28,910 |
| Feb 10, 2026 | Seely Lynn | President and CEO | A Award | 155,000 | Not measured | Not measured |
| Feb 10, 2026 | Lee Gary K. | Chief Scientific Officer | A Award | 50,000 | Not measured | Not measured |
| Feb 10, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | A Award | 8,750 | Not measured | Not measured |
| Feb 10, 2026 | Hill Stephen J. | Chief Operating Officer | S Sale | 109 | $23.12 | $2,520 |
| Feb 10, 2026 | Shook David | Chief Medical Officer | A Award | 50,000 | Not measured | Not measured |
| Feb 10, 2026 | Seely Lynn | President and CEO | S Sale | 438 | $23.12 | $10,127 |
| Feb 10, 2026 | Hill Stephen J. | Chief Operating Officer | A Award | 65,000 | Not measured | Not measured |
| Feb 10, 2026 | Lee Gary K. | Chief Scientific Officer | S Sale | 147 | $23.12 | $3,399 |
| Feb 10, 2026 | Bulis Veronica Sanchez | VP, Corporate Controller | S Sale | 254 | $23.12 | $5,872 |
| Feb 10, 2026 | Meltz Mark A | General Counsel | A Award | 50,000 | Not measured | Not measured |
| Feb 9, 2026 | Hill Stephen J. | Chief Operating Officer | A Award | 4,000 | Not measured | Not measured |
| Feb 9, 2026 | Seely Lynn | President and CEO | A Award | 20,000 | Not measured | Not measured |
| Feb 9, 2026 | Lee Gary K. | Chief Scientific Officer | A Award | 4,000 | Not measured | Not measured |
| Dec 30, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | S Sale | 936 | $32.32 | $30,252 |
| Dec 24, 2025 | Bulis Veronica Sanchez | VP, Corporate Controller | S Sale | 1,136 | $38.67 | $43,929 |
| Nov 10, 2025 | Hill Stephen J. | Chief Operating Officer | S Sale | 95 | $16.12 | $1,531 |
The full Form 4 history is on the LYEL company page (Insider Trades card, View all).
Questions about this data
Which insider transactions are open-market trades?
Code P (open market or private purchase) and code S (open market or private sale). Code F is shares withheld to pay tax on vesting stock, A is an award from the company, M and X are option exercises and G is a gift. None of those is the insider choosing to buy or sell in the market.
How quickly are insider trades reported?
A Form 4 is due before the end of the second business day after the trade. The date shown is the transaction date from the form.
Who has to file Form 4?
Officers, directors and beneficial owners of more than 10% of a class of the company’s registered equity, under Section 16 of the Securities Exchange Act.
Look up any code in the Form 4 transaction code reference, or read Form 4 codes explained.